To Top

Archives for: November 2nd, 2017

Over 140 Patient Organizations Support the Orphan Drug Tax Credit

Written by Lisa Sencen on September 14, 2017

Today, NORD joined over 140 patient organizations in sending a letter to Congress in support of the Orphan Drug Tax Credit (ODTC). We are extremely grateful to all those organizations that joined us and lent their support. It is vital that the Orphan Drug Tax Credit remains in place, and… Read More

NORD Issues Statement in Response to the Signing by President Trump of the Food and Drug Administration Reauthorization Act of 2017

Written by Lisa Sencen on August 21, 2017

Washington, D.C., August 21, 2017Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, today issued the following statement in response to the signing by President Trump of the Food and Drug Administration… Read More

NORD Releases Statement on Orphan Drug Assessment & Pricing Summit

Written by on May 31, 2017

Washington, D.C., May 31, 2017—NORD released the following statement in advance of today’s “Orphan Drug Assessment and Pricing Summit” held by the Institute for Clinical and Economic Review (ICER):

“We are pleased to participate in ICER’s ‘Orphan Drug Assessment and Pricing Summit’, and look forward to providing the… Read More